(Q45777562)
Statements
Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network (English)
R B Belshe
G J Gorse
J McElrath
M L Clements
R Dolin
D Schwartz
M C Keefer
1 December 1993